Gatifloxacin

Profiles of Drug Substances, Excipients and Related Methodology

Volumn 37, Issue , 2012, Pages 183-243

  Al Abdullah, Ebtehal S ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

8 methoxy fluoroquinolone; Anti DNA gyrase; Antibacterial; Gatifloxacin; Topoisomerases

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; CIPROFLOXACIN; ETHYLENEDIAMINE; GATIFLOXACIN; GLUCOSE TRANSPORTER 1; GLUCURONIDE; THEOPHYLLINE;

ACYLATION; ANTIBACTERIAL ACTIVITY; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BACILLUS SUBTILIS; BASE PAIRING; BIOEQUIVALENCE; CAPILLARY ELECTROPHORESIS; CARBON NUCLEAR MAGNETIC RESONANCE; CHRONIC BRONCHITIS; CHRONIC PROSTATITIS; COLORIMETRY; CONDUCTOMETRY; CYCLIZATION; DECARBOXYLATION; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXPOSURE; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG URINE LEVEL; DRUG WITHDRAWAL; ENTEROCOCCUS FAECALIS; ESTERIFICATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHY; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFRARED SPECTROSCOPY; INSULIN RELEASE; KLEBSIELLA PNEUMONIAE; LIQUID CHROMATOGRAPHY; LIVER METABOLISM; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; METHYLATION; MICROBIOLOGY; MICRODIALYSIS; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR WEIGHT; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; OTITIS MEDIA; PH; POTENTIOMETRY; PRIORITY JOURNAL; PROTEUS MIRABILIS; PROTON NUCLEAR MAGNETIC RESONANCE; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; SINGLE DRUG DOSE; SPECTROFLUOROMETRY; STREPTOCOCCUS PNEUMONIAE; TITRIMETRY; ULTRAVIOLET SPECTROPHOTOMETRY; ULTRAVIOLET SPECTROSCOPY; URINARY TRACT INFECTION; X RAY POWDER DIFFRACTION;

EID: 84858599280     PISSN: 18715125     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-397220-0.00005-2     Document Type: Chapter

References (102)

1. Lesher G.Y., Froelich E.D., Gruet M.D., Bailey J.H., Brundage R.P. 1,8-Naphthyridine derivatives. A new class of chemotherapeutic agents. J. Med. Pharm. Chem. 1962, 5:1063-1068.
2. Vinicius M., Souza N. Promising current drug candidates in clinical trials and natural products against multidrug-resistant tuberculosis. New Strategies Combating Bacterial Infection 2009, 75-76. Wiley-VCH verlag GmbH & Co. KGaA, Weinheim. I. Ahmed, F. Aqil (Eds.).
3. Mingliang L., Huiyuan G. New developments in the study of structural modification and pharmacological activity of quinolones. Zhongguo Kangshengsu Zazhi 2009, 34(Suppl.):51-59.
4. Fish D.N., North D.S. Gatifloxacin, an advanced 8-methoxy fluoroquinolone. Pharmacotherapy 2001, 21:35-59.
5. Tuberculosis. Handbook of Anti-Tuberculosis Agents Gatifloxacin 2008, Vol. 88:109-111. Issue 2, (March 2008).
6. Drug bank, 4/10/2010 at 11:30 am. http://www.drugbank.ca/search/search?query=Gatifloxacin.
7. The Merck Index 2006, Merck & Co.,Inc., White House Station,NJ, p. 753. 14th ed. S. Budavari, M.J. O'Neil, P.E. Heckelman, C.B. Koch, K.J. Roman, C.M. Kenny, M.R. D'Arecca (Eds.).
8. Martindale: The Complete Drug Referance 2002, 209-210. Pharmaceutical Press, London. 33rd ed. S.C. Sweetman (Ed.).
9. United State Pharmacopoeia, 32rd ed., United State Pharmaceutical Conversion, Inc., Rockville, MD, 2010.
10. Greta S., Valerie N., Ben-Zion D., Gideon P. Synthesis of Gatifloxacin 2004, U.S. Patent No. 4,890,470 (cf. European Patent 230,295), 2495271 A.
11. Valerie N., Ben-Zion D., Gideon P., Greta S. Novel synthesis of Gatifloxacin 2007, US Patent No. 2007,0072868 A1.
12. Milos R., Milenka R., Zdenka T., Mirjana M. Process for the preparation of gatifloxacin and regeneration of degradation products 2006, PATENTNA PISARNA D.O.O.; Copova 14, POB 1725, 1001 Ljubljana (SI). Pup. No. WO/2006/004561.
13. Shiming L., Zhenfu Q.Z., Youguang L.S. Process improvement of synthesis of gatifloxacin. Jingxi Huagong Zhongjianti 2009, 39(5):37-40.
14. Villasante F.J., Gude L., Fernndez S.P., Alonso O., Garca E., Cosme A. A high-throughput impurity-free process for gatifloxacin. Org. Process Res. Dev. 2008, 12(5):900-903.
15. Ilango K., Valentina P., Lakshmi K.S., Canhea A., Abraham S.R., Raju V.B., Kumar A.K. Indian J. Pharm. Sci. 2006, 68:273-275.
16. Ze-Quan L.I., Feng-Jing W.U., Yun G., Chang-Wen H.U., Yun-Huai Z., Meng-Yu G. Synthesis, characterization and activity against Staphylococcus of metal(II)-gatifloxacin complexes. Chin. J. Chem. 2007, 25(12):1809-1814.
17. Sivalakshmidevi A., Vyas K., Om Reddy G. Sprafloxacin, an antibacterial drug. Acta Crystallogr. C 2000, 56:e115-e116.
18. Turel I., Bukovec P., Quirós M. Crystal structure of ciprofloxacin hexahydrate and its characterization. Int. J. Pharm. 1997, 152:59-65.
19. Parvez M., Arayne M.S., Sultana N., Siddiqi A.Z. Pefloxacinium methanesulfonate 0.10-hydrate. Acta Cryst. 2000, C56:910-912.
20. Sultana N., Naz A., Arayne M.S., Mesaik M.A. Synthesis, characterization, antibacterial, antifungal and immunomodulating activities of gatifloxacin-metal complexes. J. Mol. Struct. 2010, 969(1-3):17-24.
21. Marona H.R.N., Lopes C.C.G.O., Cardoso S.G. Non-aqueous titration of gatifloxacin in pharmaceutical formulations using perchloric acid. Lat. Am. J. Pharm. 2003, 22(4):339-342.
22. Al-Ghannam S.M. Atomic absorption spectroscopic, conductometric and colorimetric methods for determination of some fluoroquinolone antibacterials using ammonium reineckate. Spectrochim. Acta A 2008, 69:1188-1194.
23. Ilango K., Valentina P., Lakshmi K.S., Arvind C., Rachel A.S., Bhaskar R.V., Kiran K.A. UV spectroscopic and colorimetric methods for the estimation of Gatifloxacin in tablet dosage forms. Indian J. Pharm. Sci. 2006, 68(2):273-275.
24. Patel P.U., Suhagia B.N., Patel C.N., Patel M.M., Patel G.C., Patel G.M. Simultaneous spectrophotometric estimation of gatifloxacin and ornidazole in mixture. Indian J. Pharm. Sci. 2005, 67(3):356-357.
25. Venugopal K., Saha R.N. New, simple and validated UV-spectrophotometric methods for the estimation of gatifloxacin in bulk and formulations. Il Farmaco 2005, 60:906-912.
26. Mali A., Dhavale R., Mohite V., Mahindrakar A., Pore Y., Kuchekar B. Spectrophotometric estimation of Gatifloxacin in tablets. Indian J. Pharm. Sci. 2006, 68(3):386-387.
27. Paramane S., Kothapalli L., Thomas A., Deshpande A.D. Simultaneous spectrophotometric estimation of gatifloxacin and ornidazole in tablet dosage form. Indian J. Pharm. Sci. 2006, 68(6):819-821.
28. Sivasubramanian L., Muthukumaran A. Spectrophotometric determination of gatifloxacin in pharmaceutical formulations and biological samples. Indian J. Pharm. Sci. 2006, 68(5):672-675.
29. Amin A.S., Gouda A.A., El-Sheikh R., Zahran F. Spectrophotometric determination of gatifloxacin in pure form and in pharmaceutical formulation. Spectrochim. Acta A 2007, 67(5):1306-1312.
30. Zhang L., Dong X., Hu W., Wang X., Jiao M. Ultraviolet characteristic of alizarin red-gatifloxacin and determination of gatifloxacin. Huaxue Yanjiu 2009, 20(4):91-94.
31. Jain P.K., Thakur A., Jain A., Modi A., Maheshwari R.K. New spectrophotometric method for the estimation of gatifloxacin in tablets using N, N-dimethylurea as hydrotropic agent. J. Global Pharma Technol. 2010, 2(3):117-119.
32. Madhuri D., Chandraekhar K.B., Somasekhar G., Harinadhababa K., Ramkotiah M., Dhandapani B. Spectrophotometric determination of Gatifloxacin through complexation with surfactant. Int. J. Pharma Sci. Res. (IJPSR) 2010, 1(2):84-89.
33. Gandhimathi M., Ravi T.K., Susheel J.V. Analysis of gatifloxacin in tablet dosage form. Indian J. Pharm. Sci. 2005, 67(6):759-762.
34. Ocaña J.A., Barragán F.J., Callejón M. Spectrofluorimetric and micelle-enhanced spectrofluorimetric determination of gatifloxacin in human urine and serum. J. Pharm. Biomed. Anal. 2005, 37:327-332.
35. Zhu X., Gong A., Yu S. Fluorescence probe enhanced spectrofluorimetric method for the determination of gatifloxacin in pharmaceutical formulations and biological fluids. Spectrochim. Acta A 2008, 69:478-482.
36. Guo C., Dong P., Chu Z., Wang L., Jiang W. Rapid determination of gatifloxacin in biological samples and pharmaceutical products using europium-sensitized fluorescence spectrophotometry fluorescence spectrophotometry. Luminescence 2008, 23(1):7-13.
37. Fu L. Measurements of gatifloxacin with a technique of energy transfer fluorescence quenching. J. Mol. Sci. Int. Ed. 2009, 25(6):407-410.
38. Wu H., Zhao G., Du L. Determination of ofloxacin and gatifloxacin by mixed micelle-mediated cloud point extraction-fluorimetry combined methodology. Spectrochim. Acta A 2010, 75:1624-1628.
39. Darwish I.A., Sultan M.A., Al-Arfaj H.A. Selective kinetic spectrophotometric method for determination of Gatifloxacin based on formation of its N-vinyl chlorobenzoquinone derivative. Spectrochim. Acta A 2010, 75:334-339.
40. Salgado H.R.N., Lopes C.C.G.O., Lucchesi M.B.B. Microbiological assay for gatifloxacin in pharmaceutical formulations. J. Pharm. Biomed. Anal. 2006, 40:443-446.
41. Abdel Ghani N.T., El-Ries M.A., El-Shall M.A. Validated polarographic methods for the determination of certain antibacterial drugs. Anal. Sci. 2007, 23(9):1053-1058.
42. El-Desoky H.S. Stability indicating square-wave stripping voltammetric method for determination of gatifloxacin in pharmaceutical formulation and human blood. J. Braz. Chem. Soc. 2009, 20(10). São Paulo. 10.1590/S0103-50532009001000004.
43. Motwani S.K., Khar R.K., Ahmad F.J., Chopra S., Kohli K., Talegaonkar S., Iqbal Z. Stability indicating high-performance thin-layer chromatographic determination of gatifloxacin as bulk drug and from polymeric nanoparticles. Anal. Chim. Acta 2006, 576(2):253-260.
44. Vishwanathan K., Bartlett M.G., Stewart J.T. Determination of gatifloxacin in human plasma by liquid chromatography/ electrospray tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2001, 15(12):915-919.
45. Nguyen H.A., Grellet J., BaB B., Quentin C., Saux M.C. Simultaneous determination of levofloxacin, gatifloxacin and moxifloxacin in serum by liquid chromatography with column switching. J. Chromatogr. B 2004, 810:77-83.
46. Liang H., Kays M.B., Sowinski K.M. Separation of evofloxacin, ciprofloxacin, gatifloxacin, moxifloxacin, trovafloxacin and cinoxacin by high-performance liquid chromatography: application to levofloxacin determination in human plasma. J. Chromatogr. B 2002, 772:53-63.
47. Overholser B.R., Kays M.B., Sowinski K.M. Determination of gatifloxacin in human serum and urine by high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. B 2003, 798:167-173.
48. Al-Dgither S., Alvi S.N., Hammami M.M. Development and validation of an HPLC method for the determination of Gatifloxacin stability in human plasma. J. Pharm. Biomed. Anal. 2006, 41:251-255.
49. Santoro M.R.M., Kassab N.M., Singh A.K., Kedor-Hackmam E.R.M. Quantitative determination of gatifloxacin, levofloxacin, lomefloxacin and pefloxacin fluoroquinolonic antibiotics in pharmaceutical preparations by high-performance liquid chromatography. J. Pharm. Biomed. Anal. 2006, 40:179-184.
50. Sultana N., Arayne M.S., Naza A. Development and validation of an HPLC-UV method for the determination of Gatifloxacin in bulk material, pharmaceutical formulations, human plasma and metal complexes. Pak. J. Pharm. Sci. 2006, 19(4):269-275.
51. Tasso L., Dalla Costa T. High performance liquid chromatography for quantification of gatifloxacin in rat plasma following automated on-line solid phase extraction. J. Pharm. Biomed. Anal. 2007, 44(1):205-210. Epub 2007 February 25.
52. Jia Z., Bingwen T., Hongbing Z., Zemin Y., Aiqun Y. Determine the contents of s-gatifloxacin by hplc. Jiepouxue Yanjiu 2009, 31(6):453-454.
53. Patel A.B., Shah N.J., Patel N.M. Development and validation of HPLC method for the simultaneous estimation of satranidazole and gatifloxacin tablet dosage form International. J. ChemTech Res. 2009, 1(3):587-590.
54. Lan T., Guofang W., Yi G., Tiegang L. Determination of gatifloxacin in gatifloxacin hydrochloride tablets by HPLC. Hebei Yike Daxue Xuebao 2009, 30(5):495-497.
55. Ramakrishna N., Srinivasulu K., Saritha V., Bujjibabu L., Vishwottam K., Koteshwara M., Hima Bindu V. High-performance liquid chromatographic method for the separation of enantiomeric. J. Chromatogr. Sci. 2010, 48(2):100-103.
56. Zhu B., Jiang S.j, Hu C.Q. Determination of gatifloxacin by high performance capillary electrophoresis. Chin. J. Pharm. Anal. 2002-2005, 1. (Abstract).
57. Sane R.T., Menon S., Pathak A.R., Deshpande A.Y., Mahale M. Capillary electrophoretic determination of gatifloxacin from pharmaceutical preparation. Chromatographia 2005, 61(5/6):303-306.
58. Lü H., Wu X., Xu C., Lin Z.X., Guo L., Yan C., Chen G. Separation and determination of seven fluoroquinolones by pressurized capillary electro-chromatography. J. Sep. Sci. 2005, 28(16):2210-2217.
59. Zhou S., Ouyang J., Baeyens W.R., Zhao H., Yang Y. Chiral separation of four fluoroquinolone compounds using capillary electrophoresis with hydroxypropyl-beta-cyclodextrin as chiral selector. J. Chromatogr. A 2006, 1130(2):296-301.
60. Yao Z., Zhang H., Wu Y., Guo H. Determination of the binding constant of bovine serum albumin and gatifloxacin using affinity capillary electrophoresis. Se Pu 2007, 25(6):930-933.
61. Sun H.-W., He P., Lv Y.-K., Liang S.-X. Effective separation and simultaneous determination of seven fluoroquinolones by capillary electrophoresis with diode-array detector. J. Chromatogr. B 2007, 852(1-2):145-151.
62. Faria A.F., de Souza M.V.N., de Oliveira M.A.L. Validation of a capillary zone electrophoresis method for the determination of ciprofloxacin, gatifloxacin, moxifloxacin and ofloxacin in pharmaceutical formulations. J. Braz. Chem. Soc. [Online] 2008, 19(3):389-396. 0103-5053, 10.1590/S0103-50532008000300004.
63. El-Bary A.A., Soliman I.I., Ali M.F.M., El-Wahed T.Y.A., El-Menshawee S.F. The photostability study of gatifloxacin under stressed conditions. J. Med. Res. Inst. 2005, 26(2):128-136.
64. Devi M.L., Chandrasekhar K.B. A validated, specific, stability-indicating RP-LC method for analysis of gatifloxacin in the presence of degradation products and process-related impurities. Chromatographia 2009, 69(9/10):985-992.
65. El-Desoky H.S. Stability indicating square-wave stripping voltammetric method for determination of gatifloxacin in pharmaceutical formulation and human blood. J. Braz. Chem. Soc. 2009, 20(10):1790-1799.
66. Ge L.K., Chen J.W., Zhang S.Y., Cai X.Y., Wang Z., Wang C.L. Photodegradation of fluoroquinolone antibiotic gatifloxacin in aqueous solutions. Chin. Sci. Bull. 2010, 55:1495-1500-1495-1500. 10.1007/s11434-010-3139-y.
67. Ge L., Chen J., Wei X., Zhang S., Qiao X., Cai X., Xie Q. Aquatic photochemistry of fluoroquinolone antibiotics: kinetics, pathways, and multivariate effects of main water constituents. Environ. Sci. Technol. 2010, 44(7):2400-2405.
68. Perry C.M., Ormrod D., Hurst M., Onrust S.V. Gatifloxacin: a review of its use in the management of bacterial infections. Drugs 2002, 62(1):169-207.
69. Lober S., Ziege S., Rau M., Schreiber G., Mignot A., Koeppe P., Lode H. Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium. Antimicrob. Agents Chemother. 1999, 43:1067-1071.
70. Wise R., Andrews J.M., Ashby J.P., Marshall J. A study to determine the pharmacokinetics and inflammatory fluid penetration of gatifloxacin following a single oral dose. J. Antimicrob. Chemother. 1999, 44:701-704.
71. Niki Y., Hashiguchi K., Miyashita N., Nakajima M., Matsushima T. Influence of gatifloxacin, a new quinolone antibacterial, on pharmacokinetics of theophylline. J. Infect. Chemother. 1999, 5(3):156-162.
72. Naber C.K., Steghafner M.A., Kinzig-Schippers M., Sauber C., Sȯrgel F., Stahlberg H.-J., Naber K.G. Concentrations of gatifloxacin in plasma and urine and penetration into prostatic and seminal fluid, ejaculate, and sperm cells after single oral administrations of 400 milligrams to volunteers. Antimicrob. Agents Chemother. 2001, 45(1):293-297.
73. Rodvold K.A., Neuhauser M. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Pharmacotherapy 2001, 21(10 Pt. 2):233S-252S.
74. Trampuz A., Laifer G., Wenk M., Rajacic Z., Zimmerli W. Pharmacokinetics and pharmacodynamics of gatifloxacin against Streptococcus pneumoniae and Staphylococcus aureus in a granulocyte-rich exudate. Antimicrob. Agents Chemother. 2002, 46(11):3630-3633.
75. Boy D., Well M., Kinzig-Schippers M., Sörgel F., Ankel-Fuchs D., Naber K.G. Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose. Int. J. Antimicrob. Agents 2004, 23(Suppl. 1):S6-16.
76. Kikuchi Junko, Yamazaki Koichi, Kikuchi Eiki, Ishizaka Akitoshi, Nishimura Masaharu Pharmacokinetics of gatifloxacin after a single oral dose in healthy young adult subjects and adult patients with chronic bronchitis, with a comparison of drug concentrations obtained by bronchoscopic microsampling and bronchoalveolar lavage. Clin. Ther. 2007, 29(1):123-130.
77. Fish D.N. Evaluation of gatifloxacin pharmacokinetics and pharmacodynamics in severely ill adults in a medical Intensive Care Unit. Int. J. Antimicrob. Agents 2007, 29:715-723.
78. Rubino C.M., Ambrose P., Cirincione B., Arguedas A., Sher L., Lopez E., Llorens S.X., Grasela D.M. Pharmacokinetics and pharmacodynamics of gatifloxacin in children with recurrent otitis media: application of sparse sampling in clinical development. Diagn. Microbiol. Infect. Dis. 2007, 59:67-74.
79. Raipuria M., Dumka V.K., Sandhu H.S. Plasma concentrations, pharmacokinetics and urinary excretion of gatifloxacin after single intravenous injection in buffalo calves. Vet. Res. Commun. 2007, 31(8):1013-1020.
80. Tasso L., Bettoni C.C., Oliveira L.K., Costa T.D. Evaluation of gatifloxacin penetration into skeletal muscle and lung by microdialysis in rats Int. J. Pharm. 2008, 358:96-101.
81. Shang-rong Z., Yan-dong W., Xia-wei D. Pharmacokinetics of gatifloxacin in ocular cornea of rabbit. Jinri Yaoxue 2009, 19(8):13-15.
82. Seiko K., Tomoyuki W., Tetsuo K., Tetsuya T., Hideyuki S., Akira O. Effect of dosing interval on the efficacy of topical ophthalmic gatifloxacin against Enterococcus faecalis in an in vitro pharmacokinetic model simulating the local eye compartment. Int. J. Antimicrob. Agents 2009, 34(6):561-565.
83. Lubasch A., Keller I., Borner K., Koeppe P., Lode H. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob. Agents Chemother. 2000, 44:2600-2603.
84. Nakashima M., Uematsu T., Kosuge K., Kusajima H., Ooie T., Masuda Y., Ishida R., Uchida H. Single- and multiple-dose pharmacokinetics of AM-155, a new 6-fluoro-8-methoxy quinolone in humans. Antimicrob. Agents Chemother. 1995, 39(12):2635-2640.
85. Stahlberge H.J., Goehler K., Guillaume M., Mignot A. Single dose pharmacokinetics of the R- and S-enantiomers of gatifloxacin in volunteers. Drugs 1999, 58(suppl 2):222-224.
86. LaCreta F., Kollia G., Duncan G., Behr D., Stoltz R., Grasela D. Effect of a high-fat meal on the bioavailability of gatifloxacin in healthy volunteers [abstr] 1998.
87. Gajjar D.A., LaCreta F.P., Kollia G.D., Stolz R.R., Berger S., Smith W.B., Swingle M., Grasela D.M. Effect of multipledose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise. Pharmacotherapy 2000, 20(6 Pt. 2):76S-86.
88. LaCreta F.P., Kollia G.D., Duncan G., Behr D., Grasela D. Age and gender effects on the pharmacokinetics of gatifloxacin. Pharmacotherapy 2000, 20(6 Pt 2):67S-75.
89. LaCreta F.P., Kaul S., Kollia G.D., Duncan G., Randall D.M., Grasela D.M. Interchangeability of 400-mg intravenous and oral gatifloxacin in healthy adults. Pharmacotherapy 2000, 20(6 Pt. 2):59S-66.
90. Gajjar D.A., LaCreta F.P., Uderman H.D., Kollia G.D., Duncan G., Birkhofer M.J., Grasela D.M. A dose-escalation study of the safety, tolerability, and pharmacokinetics of intravenous gatifloxacin in healthy adult men. Pharmacotherapy 2000, 20(6 Pt. 2):49S-58.
91. Grasela D.M., Christofalo B., Kollia G.D., Duncan G., Noveck R., Manning J.A., LaCreta F.P. Safety and pharmacokinetics of a single oral dose of gatifloxacin in patients with moderate to severe hepatic impairment. Pharmacotherapy 2000, 20(6 Pt. 2):87S-94.
92. Motoshi K., Hiroshi H., Toshihiro K., Shin'ichi M., Yamauchi D., Yasuhiko N., Shinji M., Yosuke U., Yoshitada O. Pharmacokinetic study of gatifloxacin: penetration into cerebrospinal fluid [abstr]. Jap. J. Chemother. 1999, 47(1340-7007):248-252.
93. Tsuyoshi O., Hideo H., Yoko T., Masakatsu K., Fukutaro T., Hideo O. Structural elucidation and quantification of metabolites of gatifloxacin a new quinolone, in rats, rabbits, and dogs. Jap. J. Chemother. 1999, 47(Suppl. 2):147-160.
94. Reece I.R.J., Maxwell A. DNA gyrase structure and function. Crit. Rev. Biochem. Mol. Biol. 1991, 26:335-375.
95. Grasela D.M. Clinical pharmacology of gatifloxacin a new fluoroquinolone. Clin. Infect. Dis. 2000, 31:S51-S58.
96. Blondeau J.M., Laskowski R., Bjarnason J., Stewart C. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms. Int. J. Antimicrob. Agents 2000, 14:45-50.
97. Naber K.G., Hollauer K., Kirchbauer D., Witte W. In vitro activity of gatifloxacin compared with gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens cultured from patients with complicated urinary tract infections. Int. J. Antimicrob. Agents 2000, 16:239-243.
98. Yamada C., Nagashima K., Takahashi A., Ueno H., Kawasaki Y., Yamada Y., Seino Y., Inagaki N. Gatifloxacin acutely stimulates insulin secretion and chronically suppresses insulin biosynthesis. Eur. J. Pharmacol. 2006, 553:67-72.
99. Ge T.-F., Law P.Y.P., Wong H.Y., Ho Y.-Y. Gatifloxacin affects GLUT1 gene expression and disturbs glucose homeostasis in vitro. Eur. J. Pharmacol 2007, 573:70-74.
100. Drozak J., Miecznik A., Jarzyna R., Bryla J. The inhibition of gluconeogenesis by gatifloxacin may contribute to its hypoglycaemic action. Eur. J. Pharmacol. 2008, 594:39-43.
101. Bharal N., Gupta S., Khurana S., Mediratta P.K., Sharma K.K. Anxiogenic and proconvulsant effect of gatifloxacin in mice. Eur. J. Pharmacol. 2008, 580:130-134.
102. Riahi S., Ganjali M.R., Bagheri M. Theoretical investigation of interaction between gatifloxacin and DNA: implications for anticancer drug design. Mater. Sci. Eng. C 2009, 29:1808-1813.